PT KALBE FARMA TBKPT KALBE FARMA TBKPT KALBE FARMA TBK

PT KALBE FARMA TBK

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪4.14 B‬EUR
‪162.94 M‬EUR
‪1.79 B‬EUR
‪18.72 B‬
Beta (1Y)
0.69

About KALBE FARMA

CEO
Vidjongtius
Headquarters
Jakarta
Employees (FY)
‪13.11 K‬
Founded
1966
ISIN
ID1000125107
FIGI
BBG000BXWFD1
PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical division offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores. The Consumer Health division includes over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals division sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistic division maintains distribution of the company's and third party principal's products across Indonesia; and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of LCLA is 0.10 EUR — it hasn't changed in the past 24 hours. Watch PT KALBE FARMA TBK stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange PT KALBE FARMA TBK stocks are traded under the ticker LCLA.
LCLA stock has risen by 4.81% compared to the previous week, the month change is a 7.69% rise, over the last year PT KALBE FARMA TBK has showed a 26.87% decrease.
We've gathered analysts' opinions on PT KALBE FARMA TBK future price: according to them, LCLA price has a max estimate of 0.11 EUR and a min estimate of 0.08 EUR. Watch LCLA chart and read a more detailed PT KALBE FARMA TBK stock forecast: see what analysts think of PT KALBE FARMA TBK and suggest that you do with its stocks.
LCLA reached its all-time high on Mar 7, 2018 with the price of 99.65 EUR, and its all-time low was 0.06 EUR and was reached on Mar 24, 2020. View more price dynamics on LCLA chart.
See other stocks reaching their highest and lowest prices.
LCLA stock is 0% volatile and has beta coefficient of 0.69. Track PT KALBE FARMA TBK stock price on the chart and check out the list of the most volatile stocks — is PT KALBE FARMA TBK there?
Today PT KALBE FARMA TBK has the market capitalization of ‪4.08 B‬, it has increased by 6.26% over the last week.
Yes, you can track PT KALBE FARMA TBK financials in yearly and quarterly reports right on TradingView.
PT KALBE FARMA TBK is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
LCLA earnings for the last quarter are 0.00 EUR per share, whereas the estimation was 0.00 EUR resulting in a 4.07% surprise. The estimated earnings for the next quarter are 0.00 EUR per share. See more details about PT KALBE FARMA TBK earnings.
LCLA net income for the last quarter is ‪55.91 M‬ EUR, while the quarter before that showed ‪41.33 M‬ EUR of net income which accounts for 35.27% change. Track more PT KALBE FARMA TBK financial stats to get the full picture.
Yes, LCLA dividends are paid annually. The last dividend per share was 0.00 EUR. As of today, Dividend Yield (TTM)% is 1.99%. Tracking PT KALBE FARMA TBK dividends might help you take more informed decisions.
PT KALBE FARMA TBK dividend yield was 1.93% in 2023, and payout ratio reached 51.83%. The year before the numbers were 1.82% and 52.26% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 12, 2024, the company has ‪13.11 K‬ employees. See our rating of the largest employees — is PT KALBE FARMA TBK on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PT KALBE FARMA TBK EBITDA is ‪259.18 M‬ EUR, and current EBITDA margin is 14.20%. See more stats in PT KALBE FARMA TBK financial statements.
Like other stocks, LCLA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PT KALBE FARMA TBK stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PT KALBE FARMA TBK technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PT KALBE FARMA TBK stock shows the sell signal. See more of PT KALBE FARMA TBK technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.